Core Insights - NANOBIOTIX has announced the nominations of Dr. Margaret A. Liu and Ms. Anat Naschitz as observers to its Supervisory Board, aiming to enhance its strategic initiatives in oncology and expand development opportunities [1][2][4]. Company Overview - NANOBIOTIX is a late-stage clinical biotechnology company focused on pioneering nanoparticle-based therapeutic approaches for cancer and other major diseases [1][6]. - The company is headquartered in Paris, France, and is listed on Euronext Paris and the Nasdaq Global Select Market [7]. Key Personnel - Dr. Margaret A. Liu is a global expert in vaccines, gene therapy, and cancer immunotherapy, currently serving as CEO of PAX Therapeutics and holding various board positions [2][3]. - Ms. Anat Naschitz is a life science investor and entrepreneur with over three decades of experience in biotech and pharmaceuticals, currently co-founder and CEO of 9xchange [3][4]. Strategic Goals - The company aims to leverage the expertise of Dr. Liu and Ms. Naschitz to drive the development of nanophysics-based therapies and enhance collaboration opportunities beyond its current focus on NBTXR3 [2][4]. Future Actions - The nominations of Dr. Liu and Ms. Naschitz will be submitted for ratification at the next shareholders' meeting [5].

Core Insights - Nanobiotix is a late-stage clinical biotechnology company focused on innovative physics-based approaches to enhance cancer treatment options for patients [1][3][4] - The company will participate in the H.C. Wainwright 26th Annual Global Investment Conference, scheduled for September 11, 2024, in New York City [2] Company Overview - Founded in 2003, Nanobiotix is headquartered in Paris, France, and has been listed on Euronext Paris since 2012 and on Nasdaq since December 2020 [4] - The company holds over 25 patent families related to three nanotechnology platforms, which are applicable in oncology, bioavailability and biodistribution, and central nervous system disorders [4] Event Details - The fireside chat at the conference will feature Laurent Levy, co-founder and chairman, and Bart Van Rhijn, CFO of Nanobiotix [2] - The event will be webcast live, with a replay available afterward [2]

Company Overview - Nanobiotix is a late-stage clinical biotechnology company focused on physics-based approaches to cancer treatment, headquartered in Paris, France, and listed on Euronext Paris since 2012 and on Nasdaq since December 2020 [3][7] - The company has subsidiaries in Cambridge, Massachusetts, among other locations [3] Upcoming Event - Nanobiotix will host a virtual Key Opinion Leader (KOL) event on June 18, 2024, from 9:00-10:30 AM EDT / 3:00-4:30 PM CEST [1] - The event will feature KOLs including Dr. Colette Shen, Dr. Ari Rosenberg, and Dr. Jeffrey Bockman, who will discuss NBTXR3 and its role in treating recurrent/metastatic head and neck cancer [11] Research Focus - The KOL event will cover topics such as the mechanisms of action of NBTXR3, its local and systemic responses, and the treatment landscape for head and neck cancer patients, highlighting unmet needs [12][11] - Recent data presented at the 2024 Annual Meeting of the American Society for Clinical Oncology (ASCO) will be reviewed, showing disease control and tumor response in patients treated with radiotherapy-activated NBTXR3 followed by anti-PD-1 therapy [11]

Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; "ITT") who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later line treatment 48% ORR in evaluable anti-PD-1 naïve patients (n=25); 28% ORR in evaluable anti-PD-1 resistant patients (n=25) as per RECIST 1.1 76% DCR in evaluable naïve patients; 68% DCR in evaluable resistant patients as per RECIST 1.1 Preliminary review of survival data in ITT anti-PD-1 naïve patien ...

New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer (n=68) to be presented by Coordinating Investigator Colette Shen, MD, PhD, at ASCO 2024 Following the ASCO presentation, Nanobiotix will host an investor event on Sunday, June 2nd at 12:00 PM EDT / 6:00 PM CEST to review the presented results PARIS and CAMBRIDGE, Mass., May 28, 2024 (GLOBE ...

Core Insights - Nanobiotix is presenting updated data from Study 1100, a Phase 1 trial evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer, at ASCO 2024 [1][2] - The company will host an investor event on June 2, 2024, to discuss the results presented at ASCO [1][3] Study Details - Study 1100 includes 68 patients, with early signs of efficacy observed in both anti-PD-1 naïve (n=33) and anti-PD-1 resistant (n=35) head and neck squamous cell carcinoma (HNSCC) [2] - NBTXR3 is a novel oncology product composed of functionalized hafnium oxide nanoparticles, administered via intratumoral injection and activated by radiotherapy [4] Product Development - NBTXR3 is being evaluated across multiple solid tumor indications, including a global Phase 3 study in locally advanced HNSCC [5] - The FDA granted Fast Track designation for NBTXR3 activated by radiation therapy for patients with locally advanced HNSCC who are not eligible for platinum-based chemotherapy [5] Collaboration and Strategy - Nanobiotix has engaged in a collaboration strategy to expand the development of NBTXR3, including a partnership with The University of Texas MD Anderson Cancer Center for several Phase 1 and Phase 2 studies [6] - In 2023, the company announced a license agreement for global co-development and commercialization of NBTXR3 with Janssen Pharmaceutica NV [6] Company Overview - Nanobiotix is a late-stage clinical biotechnology company focused on innovative therapeutic approaches to improve treatment outcomes for cancer patients [7] - The company is headquartered in Paris, France, and is listed on Euronext Paris and NASDAQ [8]

Financial Data and Key Metrics Changes - The company reported an unaudited cash balance of €58.9 million for Q1 2024, reaffirming a cash runway into Q3 2025, which includes a $20 million milestone received [18][21][64]. Business Line Data and Key Metrics Changes - The NBTXR3 program is the primary focus, with ongoing pivotal Phase 3 trials for head and neck cancer and a Phase 2 study for non-small cell lung cancer, both of which are expected to yield significant data in the near future [49][55]. - The company is also exploring new indications for NBTXR3 beyond head and neck and lung cancer, indicating a robust pipeline [14][30]. Market Data and Key Metrics Changes - The collaboration with Janssen Pharmaceutica is expected to expand the market potential of NBTXR3, with a deal valued at over $2.5 billion plus royalties [21][22]. - The company aims to leverage its nanoparticle technology to treat a wide range of cancers, potentially impacting millions of patients globally [6][21]. Company Strategy and Development Direction - The company is focused on executing its partnership with Janssen to maximize the value of NBTXR3 and is also exploring next-generation nanoparticle therapies [9][30]. - The strategic shift includes transferring the sponsorship of the NANORAY-312 trial to Janssen to optimize the path to market and enhance the product's value [50][63]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing collaboration with Janssen and the potential for NBTXR3 to significantly improve patient outcomes [7][22]. - The company is optimistic about the upcoming data readouts and the potential for new indications, which could further validate its technology and expand its market reach [55][92]. Other Important Information - The company has made significant operational progress, including the activation of joint working teams with Janssen and the replication of manufacturing processes to increase product availability [26][53]. - The expected interim analysis for the NANORAY-312 trial is now anticipated to be reported after the last patient is recruited in H1 2026 [12][44]. Q&A Session Summary Question: Strategies to extend the company's cash runway - Management discussed shifting focus from rapid interim readouts to expanding indications, which could lead to a more secure path forward [37][38]. - CFO noted that there are multiple options available to extend the cash runway and expressed confidence in navigating financing needs [40]. Question: Timing for the transfer of sponsorship and its impact on cash runway - Management confirmed that the transfer of sponsorship is expected to be completed before the interim readout, which could help extend the cash runway [42][86]. - The transfer is intended to be neutral initially but may become positive in the future as it allows for more focused resource allocation [87]. Question: Updates on Phase 2 in lung cancer and new platforms - Management indicated that the Phase 2 trial for lung cancer is progressing, with FDA approval received for the protocol design [92]. - Updates on the Curadigm and Oocuity platforms are expected in H2 2024, focusing on building a sustainable business model around these technologies [93][94].

PARIS and CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ''Company''), a late-clinical stage biotechnology company pioneering physics- based approaches to expand treatment possibilities for patients with cancer, today provided an update on operational progress and reported financial results for the first quarter of 2024. First Quarter Financial Updates Cash and Cash Equivalents: Based on the current operating plan and financial projections, Nanobiotix ant ...

PARIS and CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ''Company''), a late-clinical stage biotechnology company pioneering physics- based approaches to expand treatment possibilities for patients with cancer, today provided an update on operational progress and reported financial results for the first quarter of 2024. First Quarter Financial Updates Cash and Cash Equivalents: Based on the current operating plan and financial projections, Nanobiotix ant ...

PARIS and CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ''Company''), a late-clinical stage biotechnology company pioneering nanoparticle- based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced updates to its corporate strategy designed to enable long-term growth in view of significant progress in the Company's collaboration for the co-development and global commercialization of ...